331 related articles for article (PubMed ID: 10448934)
21. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide.
Ross RA; Brockie HC; Pertwee RG
Eur J Pharmacol; 2000 Aug; 401(2):121-30. PubMed ID: 10924916
[TBL] [Abstract][Full Text] [Related]
22. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
Rawls SM; Cabassa J; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
[TBL] [Abstract][Full Text] [Related]
23. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes.
Kaplan BL; Rockwell CE; Kaminski NE
J Pharmacol Exp Ther; 2003 Sep; 306(3):1077-85. PubMed ID: 12805480
[TBL] [Abstract][Full Text] [Related]
24. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
Petitet F; Jeantaud B; Capet M; Doble A
Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
[TBL] [Abstract][Full Text] [Related]
25. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
27. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system.
McAllister SD; Griffin G; Satin LS; Abood ME
J Pharmacol Exp Ther; 1999 Nov; 291(2):618-26. PubMed ID: 10525080
[TBL] [Abstract][Full Text] [Related]
29. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat.
Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190
[TBL] [Abstract][Full Text] [Related]
31. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.
Hosohata Y; Quock RM; Hosohata K; Makriyannis A; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Feb; 321(1):R1-3. PubMed ID: 9083796
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways.
Yoshihara S; Morimoto H; Yamada Y; Abe T; Arisaka O
Am J Respir Crit Care Med; 2004 Nov; 170(9):941-6. PubMed ID: 15306537
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
Ihenetu K; Molleman A; Parsons ME; Whelan CJ
Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
[TBL] [Abstract][Full Text] [Related]
34. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed.
Duncan M; Kendall DA; Ralevic V
J Pharmacol Exp Ther; 2004 Oct; 311(1):411-9. PubMed ID: 15205450
[TBL] [Abstract][Full Text] [Related]
35. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models.
Smith SR; Denhardt G; Terminelli C
Eur J Pharmacol; 2001 Nov; 432(1):107-19. PubMed ID: 11734194
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T
J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Cui YY; D'Agostino B; Risse PA; Marrocco G; Naline E; Zhang Y; Chen HZ; Finance O; Rinaldi-Carmona M; Rossi F; Advenier C
Eur J Pharmacol; 2007 Nov; 573(1-3):206-13. PubMed ID: 17643417
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats.
Germanò MP; D'Angelo V; Mondello MR; Pergolizzi S; Capasso F; Capasso R; Izzo AA; Mascolo N; De Pasquale R
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):241-4. PubMed ID: 11218077
[TBL] [Abstract][Full Text] [Related]
39. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]